Holen Sie sich die Stockscreener-App
0.3427
9.59%
0.03
Vorhandelsmarkt:
.35
0.0073
+2.13%
Schlusskurs vom Vortag:
$0.3127
Offen:
$0.3282
24-Stunden-Volumen:
1.13M
Relative Volume:
2.73
Marktkapitalisierung:
$22.90M
Einnahmen:
$1.22M
Nettoeinkommen (Verlust:
$-14.15M
KGV:
-1.3181
EPS:
-0.26
Netto-Cashflow:
$-6.55M
1W Leistung:
+22.35%
1M Leistung:
+13.85%
6M Leistung:
-3.76%
1J Leistung:
+5.41%
1-Tages-Spanne:
$0.315
$0.355
1-Wochen-Bereich:
$0.2702
$0.355
52-Wochen-Spanne:
$0.2608
$0.9099
IGC Pharma Inc Stock (IGC) Company Profile
Firmenname
IGC Pharma Inc
Sektor
Branche
Telefon
301-983-0998
Adresse
4336 Montgomery Avenue, Bethesda, MD
Vergleichen Sie IGC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IGC
IGC Pharma Inc
|
0.3427 | 22.90M | 1.22M | -14.15M | -6.55M | -0.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
495.42 | 127.22B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
689.50 | 75.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.45 | 35.94B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.43 | 31.38B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.84 | 26.84B | 3.32B | -860.46M | -1.04B | -8.32 |
IGC Pharma Inc Aktie (IGC) Neueste Nachrichten
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q3 results. We believe more positive clinical data in 2025 to be strong catalysts for stock. Raising P/T to $4.25" - ACCESS Newswire
IGC Pharma Catches Analyst Attention: $4.25 Target Set as Clinical Milestones Approach - StockTitan
IGC Pharma Announces Equity Analyst Update by Alliance Global Partners (AGP) about the "Progressing Alzheimer-targeting efforts with notable Phase 2 CALMA interim results" - ACCESS Newswire
IGC Pharma Announces Equity Analyst Update by Alliance Global Partners (AGP) about the “Progressing Alzheimer-targeting efforts with notable Phase 2 CALMA interim results” - StockTitan
IGC Pharma, Inc. (IGC) Advances AI Model to Enhance Alzheimer’s Diagnosis - Insider Monkey
12 AI Stocks Making Headlines: Latest News and Ratings - Insider Monkey
IGC Pharma Expands AI Platform With Advanced Diagnostic Model for Alzheimer's and Dementia Detection - Big News Network
Can This New AI Tool Revolutionize How Doctors Diagnose Alzheimer's Disease? - StockTitan
Ascendiant Capital Markets Issues Positive Forecast for IGC Pharma (NYSEMKT:IGC) Stock Price - Defense World
IGC Pharma expands Holiby line with ‘Longevity’, ‘Renew’ - Yahoo Finance
IGC Pharma Expands Holiby(TM) Product Line With 'Longevity' and - GuruFocus.com
IGC Pharma Expands Holiby(TM) Product Line With 'Longevity' and 'Renew'Targeting the Multi-Billion-Dollar Anti-Aging Market - Newswire
IGC Pharma's Earnings Show Major Turnaround: Net Loss Shrinks 69% While Alzheimer's Drug Shows Promise - StockTitan
IGC Pharma Reports Third Quarter Fiscal 2025 Results - ACCESS Newswire
IGC Pharma, Inc. (IGC) Reports Q3 Loss, Tops Revenue Estimates - MSN
IGC Pharma Inc. (IGC) reports earnings - Quartz
Page 3 | IGC PHARMA INC. DL -,01 Trade Ideas — FWB:IGS1 - TradingView
IGC Pharma Expands Into $75 Billion Wellness Market with the Launch of Holiby(TM) - StreetInsider.com
IGC Pharma launches Holiby wellness brand - TipRanks
IGC Pharma, Inc.: IGC Pharma Expands Into $75 Billion Wellness Market with the Launch of Holiby - finanznachrichten.de
Market Recap: IGC Pharma Inc (IGC)’s Positive Momentum, Closing at 0.32 - The Dwinnex
Alzheimer’s Clinical Trials News Roundup: Q4 - Being Patient
Page 3 | IGC PHARMA INC Trade Ideas — TRADEGATE:IGS1 - TradingView
IGC Pharma, Inc. (IGC) Upgraded to Strong Buy: What Does It Mean for the Stock? - MSN
IGC Pharma Named Top 15 Finalist in NIA PREPARE Challenge for AI-Driven Early Detection of Alzheimer's Disease - Joplin Globe
Revolutionary Voice AI Could Detect Alzheimer's Before Symptoms ShowIGC's Breakthrough - StockTitan
IGC Pharma Announces Patient Enrollment at Toronto's Baycrest in Phase 2 Trial Investigating IGC-AD1 - ACCESS Newswire
IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer’s Pipeline - ACCESS Newswire
IGC Pharma Names IGC-AD1 Phase 2 Clinical Trial for Alzheimer's Agitation "CALMA" and Expands Recruitment Strategy - ACCESS Newswire
IGC Pharma Announces Participation in BioPartnering at JPM Alongside the J.P. Morgan 43rd Annual Healthcare Conference 2025 - ACCESS Newswire
IGC Pharma Announces Publication of IMS Spotlight Interview Highlighting Strategic Expansion in Alzheimer’s and Weight Loss Therapies - ACCESS Newswire
IGC Pharma Wins 2 Prizes in Phase 1 of National Institutes of Health's AI PREPARE Challenge - ACCESS Newswire
IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets - ACCESS Newswire
IGC Pharma Appoints Former Virginia Governor Terry McAuliffe as Strategic Advisor - Markets Insider
Geode Capital Management LLC Has $240,000 Stock Holdings in IGC Pharma, Inc. (NYSEMKT:IGC) - Defense World
IGC Pharma to Unveil Alzheimer's Pipeline and AI Drug Discovery Updates at Investor Chat - StockTitan
Amazon To Sell Ad Tools To Third Parties - Baystreet.ca
IGC Gains on Word of Alzheimer’s Treatment - Baystreet.ca
Finanzdaten der IGC Pharma Inc-Aktie (IGC)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):